Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...
United States: American Society for Pharmacology and Experimental Therapeutics
Erscheinungsjahr
2003
Quelle
MEDLINE
Beschreibungen/Notizen
The clinically approved cardioprotective agent dexrazoxane (ICRF-187) and two of its hydrolyzed metabolites (a one-ring open
form of dexrazoxane and ADR-925) were examined for their ability to protect neonatal rat cardiac myocytes from doxorubicin-induced
damage. Dexrazoxane may protect against doxorubicin-induced damage to myocytes through its strongly metal-chelating hydrolysis
product ADR-925, which could act by displacing iron bound to doxorubicin or chelating free or loosely bound iron, thus preventing
site-specific iron-based oxygen radical damage. The results of this study showed that whereas dexrazoxane was able to protect
myocytes from doxorubicin-induced lactate dehydrogenase release, neither of the metabolites displayed any protective ability.
Dexrazoxane also reduced apoptosis in doxorubicin-treated myocytes. The ability of dexrazoxane and its three metabolites
to displace iron from a fluorescence-quenched trapped intracellular iron-calcein complex was also determined to see whether
the metabolites were taken up by myocytes. Although ADR-925 was taken up in the absence of calcium in the medium, in the
presence of calcium, its uptake was greatly slowed, presumably because it formed a complex with calcium. Both of the one-ring
open metabolites were taken up by myocytes and displaced iron from its complex with calcein. These results suggest either
that the anionic metabolites do not have the same access to iron pools in critical cellular compartments, that their uptake
is slowed in the presence of calcium, or, less likely, that dexrazoxane protects by some other mechanism.